Myocardial ischemia produces an energy-deficient state in heart muscle, which if not corrected can lead to cardiomyocyte death. AMP-activated protein kinase (AMPK) is a key kinase that can increase energy production in the ischemic heart. During ischemia a rapid activation of AMPK occurs, resulting in an activation of both myocardial glucose uptake and glycolysis, as well as an increase in fatty acid oxidation. This activation of AMPK has the potential to increase energy production, thereby protecting the heart during ischemic stress. However, at clinically relevant high levels of fatty acids, ischemia-induced activation of AMPK also stimulates fatty acid oxidation during and following ischemia. This can contribute to ischemic injury secondary to an inhibition of glucose oxidation, which results in a decrease in cardiac efficiency. As a result, AMPK activation has the potential to be either beneficial or harmful in the ischemic heart.
Introduction

5
0 -AMP-activated protein kinase (AMPK) controls many cellular processes, particularly pathways involved in cellular energy status.
1 AMPK is activated during metabolic stress,
and not only activates a number of energy-producing metabolic pathways, but also inhibits energy-consuming pathways. 1 As a result, AMPK can be considered a 'fuel gauge' in the cell. 1 This role of AMPK as a fuel gauge is particularly relevant in the heart, which has a very high energy demand. There are very little energy reserves in the heart, and if adenosine triphosphate (ATP) production ceased in the hearts, ATP supply would be depleted within seconds. Therefore, it stands to reason that AMPK should have a very important role as a 'fuel gauge' in the heart. This is indeed the case, and AMPK activation increases both glucose and fatty acid metabolism in times of increased metabolic demand. The role of AMPK as a fuel gauge is particularly important in the setting of cardiac ischemia. Ischemic heart disease is a major problem in western society, being the major cause of death and disability. Cardiac AMPK is rapidly activated during ischemia. [2] [3] [4] [5] [6] [7] [8] [9] [10] This activation of AMPK results in a stimulation of glucose uptake, glycolysis and fatty acid oxidation. 3, 5, 6, 11, 12 These metabolic effects can have both beneficial and harmful effects during ischemia and during reperfusion following ischemia.
Control of energy metabolism in the heart by AMPK
addition, AMPK also seems to play an important role in regulating both fatty acid and glucose metabolism. The rate at which fatty acids are taken up and oxidized by the heart is dependent on their plasma concentration, their transport into the cell, as well as the control of their intracellular utilization. There are a number of membrane transporters and enzymes involved in the transfer of substrates from the cytosol to the mitochondrial matrix. At the sarcolemmal membrane of the working heart, fatty acid translocase (FAT/CD36) has been shown to account for as much as 50% of the fatty acid acid taken up into the cell and subsequently used for oxidation.
14 A key site of control for the transport of fatty acids into the mitochondria is the enzyme carnitine palmitoyl transferase 1 (CPT-1), which is located on the outer mitochondrial membrane. This enzyme is inhibited by malonyl-CoA, the levels of which are indirectly regulated by AMPK. In the heart, levels of malonyl-CoA are controlled by the dynamic rates of its synthesis and degradation. Malonyl-CoA is synthesized from acetyl CoA in the heart by acetyl-CoA carboxylase, 15 whereas degradation of malonyl-CoA occurs by the reverse reaction through decarboxylation back to acetyl CoA by the enzyme malonyl-CoA decarboxylase. 16 Interestingly, both enzymes involved in the control of cardiac malonyl-CoA levels have been suggested to be under phosphorylation control by AMPK. Phosphorylation of acetyl CoA carboxylase by AMPK has been well documented 12 and although controversial, it has been suggested that malonyl CoA decarboxylase is also a phosphorylation target of AMPK. 17 Therefore, AMPK plays a distinct and important role in regulating both malonyl-CoA levels and fatty acid oxidation in the heart. Cardiac function is also dependent on the production of intracellular ATP derived from glucose metabolism. The initiation of glucose metabolism begins with the transport of glucose into the cell through the glucose transporters (GLUT) 1 and 4. Although GLUT1 primarily maintains basal glucose uptake, GLUT4 can be mobilized from intracellular compartments to the sarcolemmal membrane in response to insulin and/or contractile stimulation, thus increasing glucose uptake (although GLUT1 has also been shown to translocate to the plasma membrane upon insulin stimulation). 18 Once glucose is within the cell, it has a number of fates, including being stored as glycogen or undergoing glycolytic metabolism. An important enzyme at the interface between carbohydrate oxidation and fatty acid metabolism is pyruvate dehydrogenase (PDH), which decarboxylates pyruvate to acetyl CoA. PDH activity is influenced not only by glycolysis, but also by an inhibitory effect exerted through fatty acid oxidation. In situations, where the circulating free fatty acid levels are high, the oxidation of glucose and pyruvate, and the activity of PDH are decreased, due in part to an activation of pyruvate dehydrogenase kinase. Conversely, lowering plasma-free fatty acid levels, or directly inhibiting fatty acid oxidation, decreases pyruvate dehydrogenase kinase, increases PDH, increases pyruvate oxidation and cardiac efficiency (cardiac work/O 2 consumed). 12, 13 When energy demands of the heart are being met, the myocyte has the capacity to store glucose in the form of glycogen. This process is regulated by the enzyme glycogen synthase. However, when the demand for glucose increases, the myocyte begins to mobilize its glycogen stores by breaking down glycogen to glucose 1-phosphate (which is further metabolized to glucose 6-phosphate). This process is regulated by the enzyme glycogen phosphorylase. Both glycogen phosphorylase and glycogen synthase are regulated by complex mechanisms that involve either allosteric regulation by metabolites, phosphorylation/dephosphorylation control, and/or feedback inhibition by either of the products (glycogen or glucose 1-phosphate).
Whether being mobilized from glycogen or being utilized directly from the uptake process, glucose (which eventually becomes glucose 6-phosphate) can be further metabolized within the cell to produce ATP. This catabolic process can be divided into two separate categories, namely glycolysis and glucose oxidation. Glycolysis is the initial sequence of reactions involved in the breakdown of glucose to pyruvate. This process can occur without the presence of oxygen while still producing ATP. The ATP produced through this process often contributes less than 10% of the overall ATP in the normally functioning myocardium. The pyruvate generated from glycolysis is further metabolized within the mitochondria to produce the majority of carbohydrate-derived ATP (that is, glucose oxidation).
A number of enzymes are involved in the regulation of glucose uptake, glycogen storage, glycogen mobilization and glucose metabolism. Although many of these have multiple control mechanisms, a number of key enzymes in the glucose/glycogen metabolic pathways are also under phosphorylation/dephosphorylation control. AMPK has emerged as being centrally involved in the regulation of these enzymes and is thus a major regulator of cardiac energy metabolism (further discussions on glycolysis and glycogen metabolism are included below).
AMPK activation during ischemia/reperfusion
Myocardial ischemia results in a decrease in mitochondrial oxidative metabolism, and a decrease in ATP production. During mild ischemia (such as seen in angina pectoris), energy supply from mitochondrial glucose and fatty acid oxidation cannot keep up with energy demand, and glycolysis accelerates in an attempt to compensate for a decrease in mitochondrial ATP supply. During severe ischemia (such as seen during a myocardial infarction or during cardiac surgery), oxidative metabolism dramatically decreases, and the major source of ATP production is through glycolysis. However, under these conditions, glycolysis becomes uncoupled from glucose oxidation, resulting in the accumulation of deleterious byproducts of glycolysis (lactate and protons) within the cardiac cells. This can lead to the redirection of ATP away from myocardial contraction and toward the clearance of glycolytic byproducts. This leads to a decrease in both cardiac function and efficiency. 19, 20 Upon reperfusion of the reversibly injured ischemic myocardium, contractile function will recover once energy production has been restored. The extent of this recovery is dependent on the type of substrate metabolized by the heart during reperfusion. However, fatty acid oxidation can be dramatically accelerated during reperfusion, with over 95% of acetyl CoA-derived ATP originating from fatty acids (see 21 for review). These high rates of fatty acid oxidation following ischemia are due both to an increase in circulating fatty acid levels that occurs during ischemia (see 21 for review), as well as to direct alterations in the subcellular control of fatty acid oxidation. High rates of fatty acid oxidation can dramatically inhibit glucose oxidation rates through the Randle cycle, 22 as fatty acid-derived acetyl CoA decreases the production of glucose-derived acetyl CoA through inhibition of the pyruvate dehydrogenase complex. This results in a continued low rate of glucose oxidation, an uncoupling from glycolysis, and a continued decrease in cardiac efficiency during the critical period of reperfusion. During ischemia a rapid and dramatic activation of AMPK during ischemia has been well established. We first demonstrated that AMPK activation occurs during myocardial ischemia, 2,3 a finding now reproduced by numerous laboratories. 4, [7] [8] [9] [10] [11] 23, 24 This activation of AMPK presumably occurs as an approach to restore myocyte ATP levels, primarily turning on ATP generating pathways. It is now clear that AMPK activation can increase both glucose and fatty acid metabolism in the ischemic heart. Cellular control of AMPK has been widely studied, and the role of 5 0 -AMP and upstream phosphorylation of the a subunit of AMPK by AMPK kinases (AMPKKs) have been clearly established.
1 Similar control mechanisms exist in the heart, and the rapid activation of AMPK in times of stress seems to involve both increases in Similar to other organ systems, AMPK phosphorylation is a key mechanism controlling AMPK activation in the heart. Phosphorylation of Thr172 in the activation loop of the a1 and a2 subunit by upstream AMPKKs is a key mechanism by which cardiac AMPK is activated during times of metabolic stress.
1 To date, three AMPKKs have been identified in the heart, the tumor suppressor kinase LKB1, a calmodulindependent protein kinase kinase, and a TGF-b-activated kinase-1. 26 Although LKB1 and TGF-b-activated kinase-1 are highly expressed in heart, calmodulin-dependent protein kinase kinase is expressed only at low levels. 27 To date, the role of either of these AMPKKs in the control of AMPK phosphorylation and activation has not been clearly defined. However, progress is being made. For example, we 28 and others 7 have shown that an increase in AMPK phosphorylation during myocardial ischemia is accompanied by a stimulation of AMPKK activity. However, we 28 and others 29 found that this activation of AMPKK is not associated with an activation of LKB1. This suggests that either calmodulindependent protein kinase kinase is involved in AMPK phosphorylation during ischemia or that there is a presence of additional, as yet unidentified, AMPKKs in the heart. Despite the lack of alterations in LKB1 during ischemia, a role for LKB1 in ischemia-induced phosphorylation and activation of AMPK cannot be ruled out. It is of interest to note that mice hearts deficient in LKB1 show a decrease in the phosphorylation and activation of AMPKa2 during ischemia, whereas the ischemia-induced activation of AMPKa1 remains unchanged. 10 This not only suggests the presence of additional AMPKKs, but also that LKB1 does play a role in ischemia-induced activation of AMPK. As in other tissues, it is possible that metabolic stress can make AMPK a better substrate for AMPKKs LKB1. Recent evidence in endothelial cells suggests that PKC-z phosphorylates LKB1 at Ser428, resulting in an increased association of LKB1 with AMPK and consequent AMPK Thr172 phosphorylation by LKB1. 26 Whether a similar pathway exists in the heart has yet to be determined. Hormonal regulation of AMPK also involves the phosphorylation control of AMPK. Adiponectin has been shown to result in a phosphorylation and activation of cardiac AMPK, 30 although this is not a consistent finding. 31 In contrast, insulin inhibits cardiac AMPK activity, 32 as well as AMPK phosphorylation. 4,33 Exactly how insulin inhibits AMPK is not clear, although it seems to be directly mediated by protein kinase B 33,34 through a hierarchical mechanism whereby Ser485/Ser491 phosphorylation of AMPKa1/a2 by protein kinase B reduces LKB1 phosphorylation of Thr172 of AMPK. 34, 35 Confusing this issue is the observation that AMPK can inhibit cardiac insulin signaling as well, possibly through activation of an atypical protein kinase C. 36 Further characterization of the upstream AMPKKs in the heart should help clarify the relationship between hormonal control of AMPK and the phosphorylation and activation of AMPK. Although LKB1 is not activated during ischemia, a role for LKB1 in ischemia-induced phosphorylation and activation of AMPK cannot be ruled out. As in other tissues, it is possible that an increase in [AMP] could make AMPK a better substrate for AMPK. In support of this, in mice hearts deficient in LKB1 there is a decreased phosphorylation and activation of the AMPKa2 during ischemia, despite the absence of a change in LKB1 activity. It is of interest to note that the ischemia-induced activation of AMPKa1 remains unchanged. 10 This suggests that LKB1 does contribute to the ischemia-induced activation of AMPK, but that additional AMPKKs are also involved in the ischemia-induced activation of AMPK. Alternatively, the a1 isoform of AMPK may be expressed at higher levels than the a2 isoform in endothelial cells within the heart and it is the endothelial cell-specific a1 isoform that is not affected by cardiomyocyte-specific loss of LKB1.
AMPK effects on energy metabolism in the ischemic heart AMPK increases cardiac glucose utilization by a number of different mechanisms. AMPK activation promotes the translocation of GLUT4 to the sarcolemma of the myocyte, which promotes glucose uptake. 6, 8 This may involve the interaction of AMPK with the scaffolding protein TAB1, inducing p38 mitogen-activated protein kinase autophosphorylation and activation. 8 AMPK also phosphorylates and activates phosphofructokinase 2, 24 which produces fructose 2,6-bisphosphate, a potent stimulator of glycolysis. As AMPK has an important role in promoting glucose uptake and glycolysis, 24, 37, 38 the activation of AMPK during ischemia may benefit the heart by increasing glucose utilization (and subsequently anaerobic ATP synthesis). A second major metabolic consequence of AMPK activation during and following ischemia is a stimulation of fatty acid oxidation.
2,3,39 Although overall oxidative rates during ischemia are limited by oxygen supply to the muscle, during and following ischemia, AMPK activation can lower cardiac malonyl-CoA levels, secondary to phosphorylation and inhibition of acetyl CoA carboxylase. 2,3 Unfortunately, in the presence of an ischemia-induced limitation of overall oxidative metabolism, the AMPK-dependent acceleration of fatty acid oxidation occurs at the expense of glucose oxidation, and has the potential to be detrimental in the setting of ischemia/reperfusion. 3 During reperfusion, a continued activation of AMPK also contributes to fatty acid oxidation providing the majority of ATP production during the critical period of reperfusion, again at the expense of glucose oxidation.
Is AMPK activation beneficial or harmful during and following ischemia?
The question of whether AMPK activation is beneficial or harmful to the ischemic heart remains to be completely elucidated. Early studies in our laboratory implicated ischemia-induced activation of AMPK as being detrimental to the ischemic heart, primarily as the result of a stimulation of fatty acid oxidation and the subsequent inhibition of glucose oxidation (Figure 1 ). These high fatty acid oxidation rates can contribute to a decrease in cardiac function and cardiac efficiency during the critical period of reperfusion. However, the majority of studies examining AMPK activation in the ischemic heart suggest that AMPK activation is an adaptive response that allows the heart to generate ATP and thereby protect cardiac tissues in the presence of oxygen deprivation. 4, 7, 10 Unfortunately, very few of these studies
have actually examined what effect AMPK activation has directly on cardiac function. A study by Russell et al. 6 did examine what effect ischemia had on cardiac function and apoptosis in an AMPKa2 kinase dead transgenic mouse (K45Ra2). When isolated hearts perfused with low levels of fatty acids (0.4 mM oleate) were subjected to low-flow ischemia, AMPKa1 and a2 activity, glucose uptake and lactate production were all increased in wild-type mice, but not in AMPKa2 kinase dead mice. Hearts from AMPKa2 kinase dead mice showed worse function during and following ischemia, an increase in creatine kinase and lactate dehydrogenase release and an increase in caspase-3 and terminal deoxynucleotidyl transferase dUTP nick end labeling positive cells, suggesting that AMPK activation was necessary to allow hearts to withstand an ischemic insult. It is of interest to note that although fatty acid oxidation rapidly recovered during reperfusion of ischemic hearts, both rates of fatty acid oxidation and glucose oxidation were not different between wild-type and decrease cardiac efficiency in the ischemic/reperfused heart. Ischemia results in a rapid activation of AMPK in the heart. This results in a stimulation of glucose uptake, glycogenolysis and glycolysis. This can provide a potentially beneficial source of energy for the heart during an ischemia-induced decrease in mitochondrial oxidative metabolism. AMPK activation also increases fatty acid oxidation, which unfortunately results in a parallel decrease in glucose oxidation rates. In the presence of high levels of fatty acids (which is seen in most clinical scenarios of ischemia and reperfusion) a large decrease in glucose oxidation can increase proton production, because of an uncoupling of glycolysis from glucose oxidation. This can decrease cardiac efficiency and potentially contribute to ischemic injury.
beneficial effect of AMPK activation during ischemia was also observed by Shibata et al. 9 Production of an in vivo infarct in adiponectin knock-out mice had increased infarcts, decreased phosphorylation of AMPK at Thr172 and increased TNF-a and apoptosis. Administration of an adenovirusexpressing adiponectin to mice resulted in decreased infarct size, increased phosphorylation of AMPK at Thr172, and decreased TNF-a and apoptosis in the adiponectin-deficient mice. This also suggests a beneficial effect of AMPK in the setting of ischemia. However, these studies could not directly link alterations in AMPK to alterations in infarct size, and the protective effects of adiponectin were also proposed to act through other pathways, such as induction of cycloxygenase-2-dependent synthesis of prostaglandin E2. Brief periods of ischemia before a prolonged period of ischemia (called 'ischemic preconditioning') can provide significant protection to the heart. Recently, activation of AMPK has been shown to occur in the setting of ischemic preconditioning. Similar to what had been previously observed in liver, 40 ischemic preconditioning activates AMPK in the heart. 23, 41 This activation of AMPK is associated with an upregulation of GLUT4 expression, which occurs in a protein kinase C-dependent manner. 23 The activation of H11 kinase that occurs in preconditioned hearts is also associated with an activation of AMPK and promotes the translocation of AMPK to the nucleus (presumably resulting in an increase in transcription of proteins such as GLUT4). This activation of AMPK and increase in glucose uptake in ischemic preconditioning has the potential to benefit the heart. However, it has yet to be directly determined whether this activation of AMPK is associated with cardioprotection in the setting of ischemic preconditioning. Surprisingly, despite an extensive literature that has characterized the effects of ischemia on AMPK activity and the effect AMPK activation has on energy metabolism in the ischemic heart, few studies have directly linked alterations in AMPK activity with alterations in cardiac function (Table 1) . Studies in which hearts are exposed to ischemia in the presence of either no or low levels of fatty acids have suggested that hearts that have a decreased ischemiainduced activation of AMPK result in a decreased recovery of cardiac function. 6, 42 However, a recent study in hearts from mice in which AMPKa2 was deleted showed that a decrease in AMPK activation results in no difference in functional recovery following ischemia. 43 We have also recently shown in hearts from AMPK dominate negative mutant of the a2 subunit (DNa2) of mice that if hearts were exposed to either low or high levels of fatty acids there was either no difference in functional recovery, or an actual increase in functional recovery (Folmes et al., unpublished data). In addition, an increase in ischemia-induced AMPK activation in mice containing an R302Q mutation in the g2 subunit of AMPK resulted in an impaired recovery of cardiac function following ischemia (Folmes et al., unpublished data). AMPK activation during ischemia has the potential to increase energy supply to the heart by increasing glucose uptake and glycolysis. However, it also has the potential to increase fatty acid oxidation, which by inhibiting glucose oxidation can increase proton production and decrease cardiac efficiency. It is interesting to note that the study by Russell et al.
6 implying a beneficial effect of AMPK activation during ischemia was performed in the presence of low concentrations of fatty acids, a condition in which glucose oxidation rates are very high. Indeed, in their study, measured glucose oxidation rates were abnormally high, which may have minimized any adverse effect of AMPK on fatty acid oxidation stimulation. It should be pointed out that in humans, during most clinically relevant situations of myocardial ischemia, the heart is exposed to high levels of fatty acids that can exceed 1 mM. [44] [45] [46] Determining the role of AMPK in the ischemic heart is hampered by the lack of data using agonists or antagonists of AMPK in the ischemic heart. The use of AICriboside in intact hearts as an approach to activate AMPK has proved problematic, although we have found that antagonists, such as compound C, have been toxic to the heart even at doses that do not alter AMPK activity (unpublished observations). Even with the potential development of better AMPK agonists or antagonists, any short-term experiments in vitro need to be complemented by long-term experiments in intact animals to address whether AMPK deficiency enhances or inhibits myocardial ischemic injury and necrosis. It is also important to recognize that none of the published in vitro heart studies can accurately recreate plasma concentrations of saturated and unsaturated fatty acids, and triglycerides, observed in vivo. More studies using in vivo ischemia/reperfusion models would help to more clearly define whether AMPK deficiency is detrimental or protective to the heart. As a result, we believe the jury is still out as to whether AMPK is beneficial or harmful to the ischemic heart.
Conclusion
AMPK has a very important role in the heart in regulating energy metabolism. The rapid activation of AMPK during myocardial ischemia can have both beneficial and harmful effects on the heart. AMPK activation of glucose uptake and glycolysis may provide an extra source or ATP during ischemia, but if this is not accompanied by an increase in glucose oxidation, an increase in lactate and proton production can occur. Unfortunately, AMPK activation of fatty acid oxidation can prevent this increase in glucose oxidation from occurring. It is important to better define the role of AMPK in myocardial ischemia to determine whether pharmacological modification of AMPK is a potential therapeutic strategy to treat ischemic heart disease.
